SeaCrest Wealth Management LLC Purchases New Position in Illumina, Inc. (NASDAQ:ILMN)

SeaCrest Wealth Management LLC purchased a new stake in shares of Illumina, Inc. (NASDAQ:ILMNGet Rating) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 506 shares of the life sciences company’s stock, valued at approximately $93,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Tcwp LLC bought a new position in Illumina during the 1st quarter valued at about $31,000. WASHINGTON TRUST Co acquired a new stake in Illumina in the 1st quarter valued at about $35,000. Brown Brothers Harriman & Co. increased its position in Illumina by 460.9% in the 1st quarter. Brown Brothers Harriman & Co. now owns 129 shares of the life sciences company’s stock valued at $45,000 after acquiring an additional 106 shares in the last quarter. Benjamin Edwards Inc. increased its position in Illumina by 13,300.0% in the 1st quarter. Benjamin Edwards Inc. now owns 134 shares of the life sciences company’s stock valued at $47,000 after acquiring an additional 133 shares in the last quarter. Finally, Glassman Wealth Services increased its position in Illumina by 72.9% in the 2nd quarter. Glassman Wealth Services now owns 147 shares of the life sciences company’s stock valued at $27,000 after acquiring an additional 62 shares in the last quarter. 86.12% of the stock is owned by institutional investors.

Illumina Stock Down 3.1 %

Illumina stock opened at $224.68 on Friday. The company’s 50 day simple moving average is $211.03 and its 200 day simple moving average is $213.65. Illumina, Inc. has a fifty-two week low of $173.45 and a fifty-two week high of $428.00. The firm has a market capitalization of $35.34 billion, a price-to-earnings ratio of -8.51 and a beta of 1.17. The company has a debt-to-equity ratio of 0.07, a current ratio of 0.93 and a quick ratio of 0.72.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the stock. UBS Group lowered their price objective on shares of Illumina from $350.00 to $245.00 and set a “neutral” rating for the company in a research report on Wednesday, August 17th. Robert W. Baird lowered their price objective on shares of Illumina from $215.00 to $210.00 in a research report on Friday, November 4th. Citigroup lowered their price target on shares of Illumina from $220.00 to $200.00 and set a “neutral” rating for the company in a research report on Friday, August 12th. Credit Suisse Group lowered their price target on shares of Illumina from $230.00 to $225.00 and set a “neutral” rating for the company in a research report on Friday, November 4th. Finally, SVB Leerink upgraded shares of Illumina from a “market perform” rating to an “outperform” rating and lifted their price target for the stock from $220.00 to $270.00 in a research report on Tuesday, October 4th. One analyst has rated the stock with a sell rating, six have given a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $254.38.

Insider Buying and Selling at Illumina

In other Illumina news, SVP Susan H. Tousi sold 500 shares of Illumina stock in a transaction that occurred on Thursday, October 6th. The shares were sold at an average price of $216.59, for a total value of $108,295.00. Following the transaction, the senior vice president now owns 41,333 shares of the company’s stock, valued at $8,952,314.47. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.13% of the company’s stock.

Illumina Profile

(Get Rating)

Illumina, Inc provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.

Featured Articles

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.